|

Add a bookmark to get started

Bookmarks info
James Patrick McGraw

James Patrick McGraw

Asociado
Washington, DC
About

James is a corporate associate and a member of the technology and life sciences licensing and commercial transactions group at DLA Piper. He focuses his practice on representing U.S. and international clients in a wide range of strategic transactions across the life sciences and technology sectors.

James advises public and private companies, ranging from emerging growth companies to Fortune 500 companies, institutions and universities in a broad array of life sciences transactions, including license agreements, collaboration agreements, co-development and co-commercialization agreements, product acquisitions and divestitures and other complex business arrangements. In addition, James regularly negotiates manufacturing and supply agreements, distribution agreements, co-promotion agreements, sponsored research agreements, material transfer agreements, clinical trial agreements, research and development agreements and day-to-day commercial agreements that arise in the life sciences industry.

James also has broad experience counseling clients on mergers and acquisitions, venture financing, royalty monetization deals, corporate formation and governance and other general corporate matters.

Areas of FocusCiencias de la vidaCorporativoTecnologíaLife Sciences TransactionsTecnología y Transacciones ComercialesCuidado de la salud Fusiones y adquisiciones
Bar admissionsDistrito de ColumbiaPennsylvania

EXPERIENCE

  • Represented a U.S. publicly traded company in a multinational license agreement worth over $1 billion in upfront, milestone and royalty payments with a Chinese pharmaceutical company.  
  • Represented a publicly traded multinational research company based in India in a research collaboration agreement worth over $500 million with a healthcare investment company.
  • Represented an early-stage U.S. pharmaceutical company in a license agreement worth over $300 million in upfront and milestone and royalty payments with a publicly traded pharmaceutical company.
  • Represented an academic institution in a funding and research agreement worth over $250 million in laboratory funding and sponsored research with an investor-backed drug discovery enterprise.
  • Represented U.S. publicly traded company in a license agreement worth over $240 million in upfront, milestone and royalty payments with a Taiwan pharmaceutical company.
  • Represented an international pharmaceutical company in its re-negotiation of a license and collaboration agreement worth over $100 million with a U.S. pharmaceutical company. 
  • Represented an early-stage U.S. pharmaceutical company in a license agreement worth over $75 million in upfront, milestone and royalty payments with an international pharmaceutical company.
  • Represented a U.S. publicly traded company in a license agreement with an international NGO to allow suppliers to manufacture a generic version of its COVID-19 drug treatment for low-income countries.
  • Represented a an academic university in the spin-off of one of its premier laboratories into a for-profit biotechnology company and a contract development manufacturing organization.
  • Represented a publicly traded biotechnology company in a $250 million revenue interest purchase agreement with a multinational life sciences investment firm.
  • Represented a pharmaceutical company in a $150 million funding transaction with a global private equity firm.
  • Represented a U.S. publicly traded company in global manufacturing services agreement for a dedicated manufacturing facility with a leading international contract manufacturing organization.
  • Represented various pharmaceutical and biotechnology companies in the establishment of their clinical study operations, including negotiation of clinical trial agreements globally and key contract research agreements.
  • Represented various pharmaceutical and biotechnology companies in the establishment of their clinical and commercial supply chains.
 
Education
  • J.D., Temple University School of Law
    Temple Law Review
    cum laude
  • B.A., Political Science and English, Saint Joseph's University
    Phi Beta Kappa
    cum laude

Prior Experience

Before and during law school, James worked in the in-house legal department of a Fortune 100 company, where he negotiated contracts, reviewed sales and marketing materials and counselled clients on a wide range of legal and business issues.

Memberships And Affiliations

  • Member, Philadelphia Bar Association
  • Member, DC Bar Association
 

My latest insights

News

DLA Piper advises CONMED Corporation in its US$85 million acquisition of Biorez, Inc.

7 de agosto de 2022 .2 minute read

News

DLA Piper represents Intercept Pharmaceuticals, Inc. in US$450 million deal to sell...

5 de mayo de 2022 .2 minute read

Connect

Phone

+1 202 799 4359
(Work, Washington, DC)
CallvCardLinkedInPrint
Avisos legalesPolítica de cookiesPolítica de privacidad Mapa del sitio

DLA Piper es una firma de abogados global que opera a través de varias entidades legales distintas e independientes. Para obtener más información sobre esas entidades y sobre la estructura de DLA Piper, consulte la página Avisos legales de este sitio web. Todos los derechos reservados. Publicidad de abogados. © 2023 DLA Piper